Hims & Hers Health (HIMS) Cash from Investing Activities (2019 - 2026)
Hims & Hers Health's (HIMS) quarterly Cash from Investing Activities came in at -$15.4 million in Q1 2026, up 52.9% year-on-year from -$10.1 million in Q1 2025, and up 81.54% quarter-over-quarter from -$83.7 million in Q4 2025.
Hims & Hers Health (HIMS) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Hims & Hers Health has disclosed Cash from Investing Activities across 8 years of filings, most recently posting -$15.4 million for Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$15.4 million, up 52.9% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.0 billion (down 1452.89% YoY), and the FY2025 annual result was -$1.0 billion, down 5280.92% from the prior year.
- Cash from Investing Activities came in at -$15.4 million for Q1 2026 at Hims & Hers Health, up from -$83.7 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $20.7 million in Q4 2023 to a low of -$887.4 million in Q3 2025.
- The 5-year median for Cash from Investing Activities is -$4.5 million (2024), against an average of -$61.0 million.
- Across the five-year window, Cash from Investing Activities jumped 417.09% in 2024 and slumped 8421.2% in 2025, its largest moves.
- Hims & Hers Health's Cash from Investing Activities stood at $6.0 million in 2022, then soared by 244.74% to $20.7 million in 2023, then tumbled by 183.14% to -$17.2 million in 2024, then plunged by 386.32% to -$83.7 million in 2025, then surged by 81.54% to -$15.4 million in 2026.
- The last three Cash from Investing Activities figures came in at -$15.4 million (Q1 2026), -$83.7 million (Q4 2025), and -$887.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 229.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -87.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 743.70 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -506.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -60.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -2.08 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -15.45 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 25.99 Mn |
| 10 | Liquidia | 5.64 Bn | 5.42 Bn | 121.79 Mn | -2.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.45 Mn |
| Mar 31, 2026 | -15.45 Mn |
| Dec 31, 2025 | -83.68 Mn |
| Dec 31, 2025 | -83.68 Mn |
| Sep 30, 2025 | -887.40 Mn |
| Sep 30, 2025 | -887.40 Mn |
| Jun 30, 2025 | -21.09 Mn |
| Jun 30, 2025 | -21.09 Mn |
| Mar 31, 2025 | -32.80 Mn |
| Mar 31, 2025 | -32.80 Mn |
| Dec 31, 2024 | -17.21 Mn |
| Dec 31, 2024 | -17.21 Mn |
| Sep 30, 2024 | -10.41 Mn |
| Sep 30, 2024 | -10.41 Mn |
| Jun 30, 2024 | -4.47 Mn |
| Jun 30, 2024 | -4.47 Mn |
| Mar 31, 2024 | 13.04 Mn |
| Mar 31, 2024 | 13.04 Mn |
| Dec 31, 2023 | 20.70 Mn |
| Dec 31, 2023 | 20.70 Mn |